CORCEPT THERAPEUTICS INC (CORT) is a publicly traded company in the Unknown sector. Across all available filings, 40 corporate insiders have executed 1134 transactions totaling $230.6M, demonstrating a bearish sentiment with -$141.3M in net insider flow. The most recent transaction on Feb 9, 2026 involved a transaction of 150,000 shares valued at $0.
No significant insider buying has been recorded for CORT in the recent period.
No significant insider selling has been recorded for CORT in the recent period.
Based on recent SEC filings, insider sentiment for CORT is bearish with an Insider Alignment Score of 19/100 and a net flow of -$141.3M. Insiders are reducing their positions, though this can be driven by factors unrelated to company outlook.
Insider trading at CORCEPT THERAPEUTICS INC (CORT) refers to stock transactions made by corporate insiders—executives, directors, and beneficial owners holding more than 10% of the company's shares. These individuals have access to material non-public information and are required by law to report their trades to the SEC within two business days. Currently, 40 insiders are actively trading CORT stock, having executed 1134 transactions in the past 90 days. The most active insider is Joseph K. Belanoff (Executive), who has made 40 transactions totaling $119.0M.
Get notified when executives and directors at CORT file new Form 4 transactions
Date | Insider | Title | Type | Shares | Price | Value | Flags |
|---|---|---|---|---|---|---|---|
| Feb 9, 2026 | Hunt Hazel | Chief Scientific Officer | Option Exercise | 150,000 | $N/A | $0 | |
| Feb 9, 2026 | Hunt Hazel | Chief Scientific Officer | Payment | 77,968 | $41.31 | $3.2M | Large |
| Feb 9, 2026 | Hunt Hazel | Chief Scientific Officer | Option Exercise | 150,000 | $3.88 | $582.0K | Large |
| Feb 3, 2026 | Guyer William | Chief Development Officer | Option Exercise | 20,000 | $N/A | $0 | |
| Feb 3, 2026 | Guyer William | Chief Development Officer | Sale | 20,000 | $40.87 | $817.3K | Large |
| Feb 3, 2026 | Guyer William | Chief Development Officer | Option Exercise | 20,000 | $21.65 | $433.0K | |
| Jan 6, 2026 | Guyer William | Chief Development Officer | Option Exercise | 20,000 | $N/A | $0 | |
| Jan 6, 2026 | Guyer William | Chief Development Officer | Sale | 20,000 | $35.18 | $703.7K | Large |
| Jan 6, 2026 | Guyer William | Chief Development Officer | Option Exercise | 20,000 | $21.65 | $433.0K | |
| Jan 1, 2026 | Leonard Baker G. Jr | Executive | Gift | 0 | $N/A | $0 | |
| Dec 24, 2025 | K. Belanoff Joseph | Executive | Option Exercise | 550,000 | $3.88 | $2.1M | Large |
| Dec 24, 2025 | K. Belanoff Joseph | Executive | Other | 243,154 | $N/A | $0 | |
| Dec 24, 2025 | K. Belanoff Joseph | Executive | Gift | 243,154 | $N/A | $0 | |
| Dec 24, 2025 | K. Belanoff Joseph | Executive | Payment | 306,846 | $83.59 | $25.6M | Large |
| Dec 24, 2025 | Charles Robb Gary | Executive | Option Exercise | 145,000 | $3.88 | $562.6K | Large |
| TYPE | COUNT | VALUE | % |
|---|---|---|---|
Sale(S) | 382 | $185.9M | 45.0% |
Payment(F) | 56 | $106.0M | 25.7% |
Purchase(P) | 106 | $44.6M | 10.8% |
Exercise (Options)(X) | 63 | $37.3M | 9.0% |
Exercise(M) | 242 | $36.4M | 8.8% |
Gift(G) | 131 | $1.3M | 0.3% |
Award(A) | 86 | $935.4K | 0.2% |
Disposition(D) | 1 | $275.4K | 0.1% |
Other(J) | 67 | $0 | 0.0% |
Insider selling pressure at CORCEPT THERAPEUTICS INC has increased, with 40 insiders executing 1134 transactions across all time. Total sales of $185.9M significantly outpace purchases of $44.6M, resulting in a net outflow of $141.3M. This selling activity appears largely discretionary, which may warrant closer attention from investors.